Shenzhen Capital Group

Accro Bioscience is a biopharmaceutical company that specializes in the development of innovative small molecule drugs aimed at treating inflammatory and autoimmune diseases, as well as cancer. The company conducts research on the molecular mechanisms underlying regulated cell death processes, including necroptosis, pyroptosis, and ferroptosis. By understanding these mechanisms, Accro Bioscience aims to enhance current therapeutic approaches and address specific pathologies associated with various human diseases.

Nuoyimeier is a developer of implantable consumables.

Greenon Biotech specializes in the research, development, production, and promotion of alternative antibiotic preparations for animals, which primarily include bacteriophages, probiotics, plant extracts, novel acid preparations, high-efficiency disinfectants, and so on.

Maxvax Health is a biotechnology company focused on the development and commercialization of innovative vaccines. The company specializes in vaccine technology targeting viral diseases, including rotavirus, shingles, and herpes. By advancing these vaccines, Maxvax Health aims to enhance treatment options for healthcare professionals and improve patient outcomes. Through its efforts in vaccine development, the company seeks to address significant health challenges posed by viral infections.

Bio-Link is a drug development company founded in 2001 and headquartered in Shanghai, China. It specializes in providing bioprocessing solutions for the life science industry, including the development and manufacturing of key process equipment and consumables. Bio-Link's offerings include technologies for vaccines, antibody drugs, cell therapy, gene therapy, and various biologics. The company focuses on upstream cell culture, disposable dispensing reservoirs, and downstream processes such as chromatography and ultrafiltration. By delivering innovative products and services, Bio-Link aims to enhance the efficiency, safety, and competitiveness of the biopharmaceutical supply chain. Additionally, the company explores wearable technology solutions for elderly care, further diversifying its portfolio.

Wingtech Pharmaceuticals is an innovative pharmaceutical company that develop drugs for the treatment of chronic metabolic diseases.

MoleculeMind is an AI-driven protein design platform focused on revolutionizing protein discovery, optimization, and design. The company utilizes advanced AI algorithms to enhance the drug development process and has applications across various sectors, including industrial production, agriculture, material design, and environmental improvement. MoleculeMind offers an integrated biological computing platform that enables the prediction and design of peptides, antibodies, enzymes, and small proteins, facilitating industrial-scale protein optimization and design for diverse research and application needs.

Mingdu Intelligent, established in 2017 and headquartered in Hangzhou, China, specializes in providing comprehensive contract manufacturing services for pharmaceutical companies. The company offers full life cycle solutions, encompassing research and development (R&D), production, warehousing, and logistics. Mingdu Intelligent leverages an advanced information management system powered by big data and artificial intelligence to enhance the efficiency of the R&D process and streamline the application, production, and registration of pharmaceutical products.

Maxvax Health is a biotechnology company focused on the development and commercialization of innovative vaccines. The company specializes in vaccine technology targeting viral diseases, including rotavirus, shingles, and herpes. By advancing these vaccines, Maxvax Health aims to enhance treatment options for healthcare professionals and improve patient outcomes. Through its efforts in vaccine development, the company seeks to address significant health challenges posed by viral infections.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

Biosun Pharma is a biopharmaceutical company dedicated to developing drugs for cancer, autoimmune diseases, and inflammatory disorders. It focuses on molecular targeting and antibody drug development.

Hualing Technology offers pharmaceutical retail operation and management solutions. Their digital smart empowerment platform offers single store, chain store management, chain management, member management, quality management, logistics management, inventory management, smart marketing, category optimization, business intelligence bi, and interface platform.

Shenzhen TargetRx, Inc. is a high-tech pharmaceutical research and development company based in Shenzhen, China, founded in 2014. The company specializes in the research and development of third-generation small molecule targeted anti-tumor drugs aimed at addressing the challenges of drug resistance in cancer treatment. Led by Dr. Yihan Wang, an internationally recognized medical expert with extensive experience in the field, TargetRx focuses on designing, screening, evaluating, and optimizing novel pharmaceuticals for cancer patients. The company has developed a series of innovative anti-cancer solutions that possess independent intellectual property rights, with the goal of transforming cancer from a leading cause of death into a manageable chronic condition. TargetRx's commitment to advancing medical research in oncology is underscored by its dedication to improving treatment efficacy for patients facing the complexities of cancer.

Accro Bioscience is a biopharmaceutical company that specializes in the development of innovative small molecule drugs aimed at treating inflammatory and autoimmune diseases, as well as cancer. The company conducts research on the molecular mechanisms underlying regulated cell death processes, including necroptosis, pyroptosis, and ferroptosis. By understanding these mechanisms, Accro Bioscience aims to enhance current therapeutic approaches and address specific pathologies associated with various human diseases.

Mint Health is a pharmaceutical product distributor and wholesaler. MINT Health's primary business is the representation and distribution of various pharmaceutical brands in the Maltese market. MINT Health promotes wellness and self-care as natural parts of daily life. MINT Health's distribution network includes pharmacies, clinics, private hospitals, health shops, supermarkets, and central government procurement units.

Ionova Life Science Co., Ltd. is a biotechnology company founded in 2016 and based in Shenzhen, China, with additional offices in Hong Kong, Macao, and the Greater Bay Area. The company specializes in the discovery and development of novel medicines for cancer treatment, focusing on oncology, including immune-oncology and targeted delivery approaches. Ionova is dedicated to creating innovative tumor-targeted drugs and immunomodulatory therapies for cancer and related diseases, employing its proprietary discovery platform to advance its research and product development initiatives.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

Laekna Therapeutics is a clinical‑stage biotechnology company that develops novel therapies for oncology and liver disease. The company has built a comprehensive research and development platform that moves molecules from discovery to registration‑ready trials. It has initiated six clinical studies, including three multi‑regional trials targeting standard‑of‑care resistant cancers. Its lead product candidates are LAE002, an ATP‑competitive AKT inhibitor for ovarian cancer, and LAE001, a therapeutic agent for liver disease. Laekna also maintains a broader pipeline of 14 additional candidates.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.

Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

Shenzhen TargetRx, Inc. is a high-tech pharmaceutical research and development company based in Shenzhen, China, founded in 2014. The company specializes in the research and development of third-generation small molecule targeted anti-tumor drugs aimed at addressing the challenges of drug resistance in cancer treatment. Led by Dr. Yihan Wang, an internationally recognized medical expert with extensive experience in the field, TargetRx focuses on designing, screening, evaluating, and optimizing novel pharmaceuticals for cancer patients. The company has developed a series of innovative anti-cancer solutions that possess independent intellectual property rights, with the goal of transforming cancer from a leading cause of death into a manageable chronic condition. TargetRx's commitment to advancing medical research in oncology is underscored by its dedication to improving treatment efficacy for patients facing the complexities of cancer.

QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug development including phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform. The company was founded in 2017 and is based in Pudong District, Shanghai.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Remegen is a Chinese biopharmaceutical company focused on developing novel biologics, primarily monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), to address unmet medical needs in life-threatening conditions. Headquartered in Yantai with labs/offices in Beijing and California, Remegen's portfolio includes Telitacicept for systemic lupus erythematosus and Disitamab Vedotin for various cancers.

Zhimeng Biopharma, established in 2017 and headquartered in Shanghai, China, specializes in developing innovative medicines for chronic hepatitis B (CHB) and related liver diseases. Its portfolio includes HBV capsid inhibitor (CB-001), HBsAg inhibitor, TLR8 agonist, OX-40 agonist, and KCNQ2/3 K+ channel opener for epilepsy. Additionally, Zhimeng is actively exploring novel small molecule drugs to address neurological conditions like epilepsy, pains, and strokes.

Founded in 2012, Akeso Biopharma operates as a contract research organization (CRO) specializing in antibody and protein drug discovery and development. It offers integrated platforms for services such as protein expression and purification, gene-to-structure analysis, antibody generation, assay development, humanization, and affinity maturation. Serving both domestic and international biotech and pharmaceutical clients, Akeso Biopharma is headquartered in Zhongshan, China.

Hepanova is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing therapeutics for chronic liver diseases. Founded in 2014 and based in Gaithersburg, Maryland, the company pursues treatments for conditions with high unmet medical needs, including non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatic fibrosis, hepatitis B, and hepatocellular carcinoma. Hepanova operates globally, advancing multiple research programs through early and mid-stage development with the aim of offering patients innovative therapies to address liver disease.

MabPlex International Ltd is a contract development and manufacturing organization specializing in biopharmaceuticals, including monoclonal antibodies, recombinant proteins, antibody-drug conjugates, and bispecifics. Founded in 2013, the company operates from its headquarters in Yantai, China, and has an additional office in Fremont, California. MabPlex provides a comprehensive range of services that encompass all stages of drug development, from DNA to finished drug products. Its offerings include customized mammalian cell medium, cell banking, and the manufacturing of monoclonal antibody active pharmaceutical ingredients, as well as fill and finish services for biologics and antibody-drug conjugates. The company aims to deliver high-quality solutions for bio-manufacturing to its global partners.

Founded in 2012, Akeso Biopharma operates as a contract research organization (CRO) specializing in antibody and protein drug discovery and development. It offers integrated platforms for services such as protein expression and purification, gene-to-structure analysis, antibody generation, assay development, humanization, and affinity maturation. Serving both domestic and international biotech and pharmaceutical clients, Akeso Biopharma is headquartered in Zhongshan, China.

Teligene Ltd., established in 2011 and headquartered in Jiangsu, China, is a pharmaceutical research and development company specializing in the creation of small-molecule drugs for oncology. The company's senior management team, experienced in advanced drug development technologies, focuses on researching and developing innovative, targeted anti-tumor drugs with independent intellectual property rights.

Shenzhen TargetRx, Inc. is a high-tech pharmaceutical research and development company based in Shenzhen, China, founded in 2014. The company specializes in the research and development of third-generation small molecule targeted anti-tumor drugs aimed at addressing the challenges of drug resistance in cancer treatment. Led by Dr. Yihan Wang, an internationally recognized medical expert with extensive experience in the field, TargetRx focuses on designing, screening, evaluating, and optimizing novel pharmaceuticals for cancer patients. The company has developed a series of innovative anti-cancer solutions that possess independent intellectual property rights, with the goal of transforming cancer from a leading cause of death into a manageable chronic condition. TargetRx's commitment to advancing medical research in oncology is underscored by its dedication to improving treatment efficacy for patients facing the complexities of cancer.

Zelgen is a biopharmaceutical company based in Suzhou, China, dedicated to the innovation, research, development, manufacture, and sales of new medications. The company aims to establish itself as a leader in the Chinese biopharmaceutical industry, focusing on treatments for cancer, hematologic diseases, and other significant health challenges. Zelgen's business strategy emphasizes addressing unmet medical needs within the domestic market by developing high-quality, safe, effective, and affordable medications. The company's research and development efforts encompass new chemical and biological drugs across various therapeutic areas, including tumors and liver-related diseases.

Founded in 2012, Akeso Biopharma operates as a contract research organization (CRO) specializing in antibody and protein drug discovery and development. It offers integrated platforms for services such as protein expression and purification, gene-to-structure analysis, antibody generation, assay development, humanization, and affinity maturation. Serving both domestic and international biotech and pharmaceutical clients, Akeso Biopharma is headquartered in Zhongshan, China.

Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the discovery, development, and manufacturing of innovative medicines aimed at improving patient health. Founded in 2013, the company addresses unmet medical needs primarily in anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch designed for musculoskeletal joint pain relief. Additionally, the company is developing a combination regimen of Albuvirtide and 3BNC117, a monoclonal antibody targeting HIV-1 viruses. Frontier Biotech's commitment to excellence spans the entire development cycle, from drug discovery to global clinical trials, with multiple candidates currently in Phase I and Phase II trials in both China and the United States. The company's focus on long-acting therapies and differentiated products positions it as a competitive player in the biopharmaceutical industry.

Zelgen is a biopharmaceutical company based in Suzhou, China, dedicated to the innovation, research, development, manufacture, and sales of new medications. The company aims to establish itself as a leader in the Chinese biopharmaceutical industry, focusing on treatments for cancer, hematologic diseases, and other significant health challenges. Zelgen's business strategy emphasizes addressing unmet medical needs within the domestic market by developing high-quality, safe, effective, and affordable medications. The company's research and development efforts encompass new chemical and biological drugs across various therapeutic areas, including tumors and liver-related diseases.

Founded in 2012, Akeso Biopharma operates as a contract research organization (CRO) specializing in antibody and protein drug discovery and development. It offers integrated platforms for services such as protein expression and purification, gene-to-structure analysis, antibody generation, assay development, humanization, and affinity maturation. Serving both domestic and international biotech and pharmaceutical clients, Akeso Biopharma is headquartered in Zhongshan, China.

JHOME develops diagnostic and medical imaging technologies and operates as an importer/exporter and Internet B2C platform for drugs and medical devices. It manufactures and distributes in vitro diagnostic reagents and instruments, medical imaging systems, and medical electronic equipment, with a focus on product and technological innovation in medical care, family health, and public safety. Its offerings include proprietary immunoassay platforms, portable diagnostic devices, and CE-certified reagents that enable hospitals, pharmacies, and disease control centers to deliver rapid detection, improved patient monitoring, and broader healthcare accessibility.

Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, specializes in the development of oncolytic virus therapeutics aimed at treating cancer. The company utilizes its innovative Synerlytic™ technical platform to enhance cancer treatment through novel immunotherapy approaches. Virogin's technology focuses on leveraging immunological principles to stimulate anticancer and antitumor immunity. By harnessing a robust and transient antiviral immune response, the company aims to improve systemic antitumor immunity via synergistic interactions with multiple therapeutic payloads. Virogin is dedicated to advancing its position as a leader in the field of immuno-oncology.

Shenogen Pharma Group is a drug discovery and development company.

Suzhou Tianma Medical Group is a large-scale technology enterprise that integrates fine chemicals, bio-pharmaceuticals, and tourism real estate. The company has focused on industrialization and standardization to develop a robust operational model that fosters the interaction between capital and industrial activities. Suzhou Tianma Medical Group has transitioned from producing traditional pharmaceutical intermediates and ingredients to full pharmaceutical preparations, establishing itself as a key supplier of domestic crude drugs. The company's product offerings span several sectors, including fine chemicals, advanced pharmaceutical intermediates, pharmaceutical raw materials, and paper-making chemicals. Through strategic investments and technological innovation, the group actively seeks opportunities for industrial expansion and development.

Rundo Medical is a contract research organization (CRO) that focuses on providing comprehensive clinical research outsourcing services to pharmaceutical and biotechnology companies. It specializes in a range of high-quality solutions, including clinical operations, medical data management, biostatistics, and medical project management. As a prominent player in the CRO industry, Rundo Medical is a key initiator and promoter of the China CRO Alliance. The company has distinguished itself by being the first in its sector to achieve ISO 9001:2008 quality management system certification, combined with CRO industry standard certification. Through its professional services, Rundo Medical supports various clients in advancing their medical research and operational objectives.

Jilin Connell Pharmaceutical is a pharmaceutical manufacturing company. They produce oral solid preparations, mixtures, and oral liquids. It also provides thymosin enteric-coated tablets, which are also used clinically in the treatment of low-immunity diseases such as tumors, acute pancreatitis, and systemic lupus.

Weifang Pharmaceutical Factory Co., Ltd. (潍坊制药厂) is a Chinese joint-stock pharmaceutical enterprise that integrates production and operation, research and development, as well as domestic and foreign trade. The company currently has assets of 0.154 billion Yuan. It has over 50 steady dealers and agencies who sell products directly to nearly 3,000 hospitals in big- and medium-sized cities all over the country. Its generic drug products are sold to markets of small- and medium-sized cities and villages, while bulk drug products are mainly sold to drug markets in Europe and the United States. Weifang Pharmaceutical Factory was founded in 1966.

Shanghai Celgen Biopharma Co., Ltd. is a biopharmaceutical company specializing in the research, development, production, and sales of biological medicinal products, particularly recombinant proteins and monoclonal antibodies aimed at treating immune diseases and cancer. The company has established a robust professional platform that includes a phage antibody screening library and a CHO cell clone development platform, both recognized by regulatory bodies such as the FDA and EMEA. Additionally, Celgen Biopharma has developed advanced capabilities for serum-free and antibiotic-free CHO cell culture, along with sophisticated purification and analytical platforms. Their focus on innovative technology and quality design underpins their commitment to improving patient health outcomes through effective biologic drugs.

Hubei Xunda Pharmaceutical Co., Ltd. is a modern Chinese pharmaceutical company specializing in the production of anti-inflammatory and analgesic drugs, as well as bulk pharmaceutical chemicals for antibiotics and pharmaceutical intermediates. Its product portfolio includes key items such as ketoprofen, felbinac, and various forms of fosfomycin, which are distributed to markets in Japan, Korea, the Middle East, Europe, and America. The company is equipped with advanced production and testing facilities, ensuring high-quality output supported by strong technical expertise and management practices. Hubei Xunda Pharmaceutical holds several invention patents and has achieved certifications including Chinese GMP and the European COS certificate for its ketoprofen product, underscoring its commitment to regulatory compliance and product excellence.

Hybio Pharmaceutical Co., Ltd. is a peptide pharmaceutical company based in Shenzhen, China, specializing in the research, development, manufacture, and sale of polypeptide drugs. Founded in 1998, the company offers a diverse range of products, including finished dosage forms for digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. Additionally, Hybio provides custom peptides and active pharmaceutical ingredients (APIs), along with contract research and manufacturing services. The company adheres to stringent production management and quality control standards, which have enabled it to innovate and enhance large-scale production technologies for polypeptide drugs. Hybio has also been active in securing intellectual property, having applied for numerous patents and obtained various drug certifications, further solidifying its position in the pharmaceutical industry.

Suzhou Tianma Medical Group is a large-scale technology enterprise that integrates fine chemicals, bio-pharmaceuticals, and tourism real estate. The company has focused on industrialization and standardization to develop a robust operational model that fosters the interaction between capital and industrial activities. Suzhou Tianma Medical Group has transitioned from producing traditional pharmaceutical intermediates and ingredients to full pharmaceutical preparations, establishing itself as a key supplier of domestic crude drugs. The company's product offerings span several sectors, including fine chemicals, advanced pharmaceutical intermediates, pharmaceutical raw materials, and paper-making chemicals. Through strategic investments and technological innovation, the group actively seeks opportunities for industrial expansion and development.

Xi'an Haotian Biological Engineering technology Co., Ltd (西安皓天) is a Chinese raw material supplier to the global health industry. Xi'an Haotian is specialized in manufacturing quality and reliable raw materials for many industries including functional food, nutritional supplement, cosmetic, pharmaceutical, and feed. It is one of the main raw material exporters in the health industry in China. The researchers in the firm accounts for 31.8% of total number including five doctors and fifteen masters, who are specialized in the fields of extraction and separation, synthetizing, fermenting, pharmacy, dietetics, and more. Xi'an Haotian was established in February 2003.

Inner Mongolia Mongolian Pharmaceutical is a pharmaceutical enterprise integrating planting, production, sales, and research and development of medicinal materials. They provide products for rheumatic bone disease, respiratory system, kidney disease, gastrointestinal tract, cardiovascular, and other.